Amplify Weight Loss Drug & Treatment ETF
THNR
4 hedge funds and large institutions have $994K invested in Amplify Weight Loss Drug & Treatment ETF in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
37% more capital invested
Capital invested by funds: $727K → $994K (+$267K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
2.63% less ownership
Funds ownership: 23.23% → 20.6% (-2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
+$342K |
| 2 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$77.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$179K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $390K | -$179K | -6,656 | -31% |
|
|
GS
2
GTS Securities
New York
| $341K | +$342K | +12,740 | New |
|
|
HI
3
Harbour Investments
Madison,
Wisconsin
| $256K | +$77.7K | +2,895 | +43% |
|
|
4
UBS Group
Zurich,
Switzerland
| $5.95K | +$5.96K | +222 | New |
|
THNR Hedge Fund Activity: Q3 2024 in Review
4 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q3 2024, worth a combined $994K — up 37% from $727K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new THNR positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was GTS Securities, opening a new position worth an estimated $342K. The largest seller was Jane Street, cutting an estimated $179K.
- 4 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q3 2024, up from 2 in Q2 2024.
- Funds reported $994K of Amplify Weight Loss Drug & Treatment ETF stock for Q3 2024, up 37% quarter-over-quarter.
- 2 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q3 2024 and 0 closed out, a net change of +2 holders.
- The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q3 2024 was GTS Securities, an estimated $342K added.
- The largest Amplify Weight Loss Drug & Treatment ETF seller in Q3 2024 was Jane Street, an estimated $179K sold.
Based on aggregated 13F filings for Q3 2024.